| abstract |
The present disclosure relates to a method for treating a haematological malignancy or pre-malignant condition in a subject. In one particular application, the method involves administering to a subject with Acute Myeloid Leukaemia (AML) and preferably an AML overexpressing miR-10a (eg NPMc+ AML), an effective amount of a first agent comprising an MDM2/MDMX inhibitor (eg Nutlin-3a), a second agent comprising an inhibitor of MiR-10a expression and/or activity (eg an antisense oligonucleotide targeted to MiR-10a), and optionally, a chemotherapeutic agent such as a "standard of care" (SOC) chemotherapeutic agent for AML (eg cytarabine). |